Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.55 |
| ▸ | REN | P00797 | 1/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769315 | 1.00 | ACE (0.58) | ACEOPRK1F2PSMB9REN | |
| SCHEMBL20769314 | 1.00 | ACE (0.58) | ACEOPRK1F2PSMB9REN | |
| SCHEMBL31512206 | 0.97 | ACE (0.58) | ACEOPRK1F2PSMB9REN | |
| SCHEMBL30469506 | 0.90 | ACE (0.59) | ACEOPRK1F2OPRM1 | |
| SCHEMBL2195454 | 0.88 | OPRD1 (0.55) | ACEOPRK1F2PSMB9REN | |
| SCHEMBL29473876 | 0.87 | CAPN1 (0.47) | ACENTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30259604 | 0.85 | REN (0.53) | ACEOPRK1F2RENNTSR2 | |
| SCHEMBL3221787 | 0.85 | OPRK1 (0.59) | OPRK1F2NTSR2NTSR1OPRM1 | |
| SCHEMBL3221767 | 0.85 | OPRK1 (0.59) | OPRK1F2NTSR2NTSR1OPRM1 | |
| Thymoctonan SCHEMBL15532000 | 0.85 | REN (0.52) | ACEOPRK1F2RENNTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ACE 1799/4885OPRK1 2737/4885F2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.